Mathias Schmidt
Direktor/Vorstandsmitglied bei JCR PHARMACEUTICALS CO., LTD.
Profil
Mathias Schmidt is currently the Chief Executive Officer & Director at ArmaGen, Inc. and MD, Head-Clinical & Business Development at JCR Pharmaceuticals Co., Ltd.
He is also the President & Chief Executive Officer at JCR USA, Inc. Dr. Schmidt holds a doctorate degree from the University of Freiburg and a graduate degree from Universität Stuttgart.
Aktive Positionen von Mathias Schmidt
| Unternehmen | Position | Beginn |
|---|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Direktor/Vorstandsmitglied | 01.06.2020 |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Vorstandsvorsitzender | - |
| JCR USA, Inc. | Vorstandsvorsitzender | - |
Ausbildung von Mathias Schmidt
| University of Freiburg | Doctorate Degree |
| Universität Stuttgart | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
| JCR USA, Inc. |
